Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tc 99m NC 100586

Next Previous
Drug Profile

Tc 99m NC 100586

Alternative Names: 99m-Tc-NC100586

Latest Information Update: 08 Sep 2006

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GE Healthcare; Targeted Diagnostics and Therapeutics
  • Developer GE Healthcare; Targeted Diagnostics and Therapeutics; Thomas Jefferson University
  • Class Cyclopropanes; Fluoroquinolones; Heavy metals; Imaging agents; Piperazines; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 08 Sep 2006 Discontinued - Preclinical for Solid tumour diagnosis in USA (IV)
  • 16 Apr 2004 Amersham has merged with GE Medical Systems to form GE Healthcare
  • 14 Nov 2002 A preclinical study has been added to the pharmacokinetics and Cancer pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top